ALT at a glance
Altimmune, Inc. (ALT, SEC CIK 1326190) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 29, 2026 and Form 4 insider filings as recently as October 5, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Altimmune, Inc. (ALT) reported revenue of $41,000 (up 105.0% from FY2024) and a net loss of $88.1 million. Diluted EPS was -$1.00.
- As of June 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Altimmune, Inc. (ALT) shares worth $218.1 million in 13F-HR filings.
- In the last 90 days, ALT insiders reported 1 open-market purchase ($44K) and 0 open-market sales ($0) on Form 4, a net purchase of $44K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $41K
- +105.0% vs prior year
- Insiders · 90 days
- 1 buy · 0 sells
- Net +$44K
- 13F holders
- 28 funds
- $218.1M · +1 vs prior quarter
- Latest 8-K
- Sep 29, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Revenue $0 vs $5 thousand, down 100% YoY
- Net loss $22.825M vs $22.146M; operating loss $26.229M vs $22.922M
- ALD R&D $4.604M, up 199%; MASH R&D $3.795M, down 30%
- Cash, equivalents, restricted cash and short-term investments $326.3M; long-term investments $192.3M
- Operating cash use $45.163M vs $36.190M; April offering generated $211.1M net proceeds
Risk Factors
- No material changes from 10-K risk factors filed March 6, 2026
- Carried-forward risks remain the company’s most significant disclosed risk factors
- No newly triggered regulatory, legal, operational, competitive, or market risk identified
- No quarter-specific liquidity, debt maturity, currency, or concentration risk disclosed
AI summary of the ALT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Richard Menziuso appointed Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026
- CFO Gregory Weaver remains in role, indicating accounting leadership change without CFO turnover
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1, containing the detailed financial results
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $22.8M, or $0.12 per share, versus $22.1M and $0.27 in Q2 2025
- Cash, cash equivalents and investments $519M at June 30, 2026, supporting continued clinical development
Item 7.01: Regulation FD Disclosure
- Positive topline RECLAIM Phase 2 results for pemvidutide 2.4 mg in moderate-to-severe alcohol use disorder
- Pemvidutide’s dual glucagon/GLP-1 mechanism expands potential beyond metabolic indications
Item 8.01: Other Events
- RECLAIM Phase 2 met its primary endpoint with highly significant reduction in heavy drinking days versus placebo
- Positive secondary outcomes included FDA registrational endpoints: two-level WHO risk reduction and zero heavy drinking days
Item EX-99.1: Item EX-99.1
- RECLAIM Phase 2 met its primary endpoint: HDD/week improved by 1.45 days versus placebo at Week 24, p=0.0014
- FDA-recognized registrational endpoints succeeded: two-level WHO-RDL reduction 64.4% vs 34.8%, zero HDD 42.2% vs 17.4%
AI summaries of ALT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ALT
Don't miss the next ALT filing
- Alerts as it files. A push when ALT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ALT, by share count.
- Ask anything. An AI agent that reads every ALT filing and answers with sources.
ALT alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Arbet-Engels Christophe | F | Oct 1, 2026 | 12,679 | $2.76 |
| WEAVER GREGORY L | M | Oct 1, 2026 | 14,475 | - |
| Arbet-Engels Christophe | M | Oct 1, 2026 | 37,500 | - |
| Arbet-Engels Christophe | M | Oct 1, 2026 | 37,500 | - |
| MENZIUSO RICHARD THOMAS | A | Oct 1, 2026 | 84,546 | - |
| MENZIUSO RICHARD THOMAS | A | Oct 1, 2026 | 36,234 | - |
| WEAVER GREGORY L | F | Oct 1, 2026 | 4,379 | $2.76 |
| WEAVER GREGORY L | M | Oct 1, 2026 | 14,475 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $20K | $41K |
| Operating Income | -$95.9M | -$103.2M | -$94.5M |
| Net Income | -$88.4M | -$95.1M | -$88.1M |
| Op. Margin | - | -515860.0% | -230461.0% |
| Net Margin | - | -475295.0% | -214861.0% |
| Balance Sheet | |||
| Total Assets | $210.6M | $139.3M | $279.9M |
| Equity | - | $123.5M | $224.9M |
| ROE | - | -77.0% | -39.2% |
| Per Share | |||
| EPS | $-1.66 | $-1.34 | $-1.00 |
| Cash Flow | |||
| Operating CF | -$75.8M | -$79.8M | -$67.5M |
| CapEx | - | - | $11K |
Source: XBRL data in Altimmune, Inc. (ALT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ALT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 28 | $218.1M |
| Q1 2026 | 27 | $138.0M |
| Q4 2025 | 25 | $127.0M |
| Q3 2025 | 24 | $97.3M |
| Q2 2025 | 25 | $81.6M |
| Q1 2025 | 22 | $77.1M |
| Q4 2024 | 19 | $129.1M |
| Q3 2024 | 16 | $69.4M |
- BlackRock+7.59M (+59%)
- State Street Corp+4.95M (+69%)
- Vanguard Capital Management LLC+2.52M (+45%)
- Vanguard Portfolio Management LLC+1.95M (+36%)
- AQR Capital Management+1.14M (+1329%)
- D.E. Shaw & Co−525.4K (-72%)
- Dimensional Fund Advisors−406.5K (-39%)
- Two Sigma Investments−97.8K (-4%)
- Raymond James Financial−32.4K (-60%)
- JPMorgan Chase & Co−20.9K (-16%)
- U.S. Bancorp−890
Source: 13F-HR filings on SEC EDGAR (aggregated from 186 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ALT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 2, 2026 | - | - | - |
| 8-K | Sep 29, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 3, 2026 | - | - | - |
| 4 | Aug 3, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 10-Q | May 13, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 13, 2026 | - | Analysis | |
| SC 13G | May 12, 2026 | - | - | |
| 4 | May 1, 2026 | - | - | - |
| SC 13G | May 1, 2026 | - | - | |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| 4 | May 1, 2026 | - | - | - |
| SC 13G | May 1, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
ALT SEC filings: frequently asked questions
Are ALT insiders buying or selling?
In the last 90 days, Altimmune, Inc. (ALT) officers, directors and 10% owners reported 1 open-market purchase worth $44,250 by 1 insider and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ALT stock?
As of June 30, 2026, the largest Altimmune, Inc. (ALT) holders among the 13F filers tracked by SignalX were BlackRock ($62.0 million), State Street Corp ($36.8 million), Vanguard Capital Management LLC ($24.9 million), Vanguard Portfolio Management LLC ($22.3 million), Viking Global Investors ($20.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ALT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Altimmune, Inc. (ALT) reported revenue of $41,000 (up 105.0% from FY2024) and a net loss of $88.1 million. Diluted EPS was -$1.00. The figures come from the XBRL data in the 10-K.
What did ALT report in its latest 8-K?
Altimmune, Inc. (ALT) filed an 8-K on September 29, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Richard Menziuso appointed Vice President, Global Controller and Principal Accounting Officer effective September 29, 2026.
What are the latest ALT SEC filings?
Altimmune, Inc. (ALT) filed its latest 10-K annual report on March 6, 2026, a 10-Q quarterly report on August 12, 2026, an 8-K current report on September 29, 2026 and a Form 4 insider filing on October 5, 2026.
What is ALT's SEC CIK number?
Altimmune, Inc. (ALT)'s SEC Central Index Key (CIK) is 1326190. EDGAR lists every ALT filing under that number.
Ask anything about ALT
The research agent reads ALT's filings, financials, insider trades and 13F holders, then answers with sources.